CTOs on the Move

scPharmaceuticals

www.scpharmaceuticals.com

 
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

scPharmaceuticals raised $45.6M on 01/04/2017
scPharmaceuticals raised $65M on 05/18/2020

Similar Companies

Montclair Park At Poulsbo

Montclair Park At Poulsbo is a Poulsbo, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthLeaders-InterStudy

HealthLeaders-InterStudy is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.

Fluresh

Fluresh is a premium vertically integrated medical & adult use cannabis company obsessed with quality and wellness. We believe that each individual connection between a patient and cannabis is unique, dynamic and matchless.

Omega Protein

Omega Protein Corporation was a publicly traded US company, founded in 1913 as a fishing operation.